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Target volume determination in radiotherapy 
for non-small-cell lung cancer – facts and questions
Lucyna K´pka, Krzysztof Bujko
Although the precise target volume definition in conformal radiotherapy is required by ICRU Report 50 and 62, this task in
radiotherapy for non-small-cell lung cancer (NSCLC) is often controversial and strict accordance with ICRU requirements
is hard to achieve. The Gross Tumour Volume (GTV) definition depends mainly on the imaging method used. We discuss the
use of new imaging modalities, like PET, in GTV definition. The Clinical Target Volume (CTV) definition remains a separate,
and still unresolved problem, especially in the part concerning the Elective Nodal Irradiation (ENI). Nowadays, there is no
unified attitude among radiation oncologists regarding the necessity and extent of ENI. The common use of combined
treatment modalities and the tendency to dose escalation, both increasing the potential toxicity, result in the more frequent use
of involved-fields techniques. Problems relating to margins during Planning Target Volume (PTV) of lung cancer irradiation
are also discussed. Another issue is the Interclinician variability in target volumes definition, especially when there is data
indicating that the GTV, as defined by 3 D-treatment planning in NSCLC radiotherapy, may be highly prognostic for survival.
We postulate that special attention should be paid to detailed precision of target volume determination in departmental
and trial protocols. Careful analysis of patterns of failures from ongoing protocols will enable us to formulate the guidelines
for target volume definition in radiotherapy for lung cancer.
Wyznaczanie obszarów do napromieniania w radioterapii niedrobnokomórkowego raka p∏uca
Dok∏adne okreÊlenie obszarów do napromieniania, zgodnie z wymaganiami ICRU (International Commission on Radiation
Units and Measurements), jest obecnie jednym z kryteriów poprawnoÊci stosowania radioterapii konformalnej. Spe∏nienie kry-
teriów ICRU, odnoÊnie definiowania poszczególnych obszarów do napromieniania (GTV, CTV, PTV), napotyka w radiotera-
pii niedrobnokomórkowego raka p∏uca na szczególne trudnoÊci. Znane sà du˝e ró˝nice w okreÊlaniu makroskopowej obj´toÊci
guza (GTV) pomi´dzy lekarzami, nawet w obr´bie jednego oÊrodka. Wià˝e si´ to z trudnoÊcià w interpretacji danych radio-
logicznych w przypadku raka p∏uca, brakiem protoko∏ów i szczegó∏owych instrukcji, dotyczàcych tego zagadnienia, a tak˝e
stosowaniem ró˝nych technik diagnostycznych. Zale˝noÊç wielkoÊci GTV od stosowanych technik obrazowania, w szczegól-
noÊci zalety i ograniczenia pozytronowej tomografii emisyjnej (PET), sà dyskutowane w artykule. Osobny i nierozwiàzany pro-
blem w radioterapii raka p∏uca stanowi definicja klinicznej obj´toÊci tarczowej (CTV). W artykule omówiono fakty i pytania
dotyczàce okreÊlania CTV jako mikroskopowego szerzenia si´ choroby w bezpoÊrednim sàsiedztwie GTV, a tak˝e aspekty zwià-
zane z CTV, okreÊlanym jako obszar elektywnego napromieniania (OEN) w´z∏ów ch∏onnych Êródpiersia. Obecnie OEN
stanowi temat badaƒ klinicznych. W dobie powszechnego stosowania chemio-radioterapii i eskalacji dawki promieniowania,
a tak˝e skracania czasu leczenia, istnieje tendencja do zmniejszania obszaru napromieniania. ToksycznoÊç zwiàzana z napro-
mienianiem elektywnym, w Êwietle wielu doniesieƒ, prowadzi do obni˝enia zysku terapeutycznego w radioterapii raka p∏uca.
Dyskutowane sà problemy zwiàzane z ustalaniem wielkoÊci marginesów, celem utworzenia Planowanej Obj´toÊci Tarczowej
(PTV). Wobec wielu kontrowersji zwiàzanych z definiowaniem obszarów do napromieniania w radioterapii raka p∏uca,
przy jednoczesnych doniesieniach, ˝e GTV jest czynnikiem prognostycznym, nale˝y bardzo szczegó∏owo definiowaç obj´toÊci
do napromieniania w protoko∏ach poszczególnych oÊrodków. Istniejà doniesienia, ˝e wprowadzenie Êcis∏ych protoko∏ów, zwià-
zanych z definiowaniem obszarów do napromieniania, prowadzi do znacznego zmniejszenia ró˝nic w zakresie „wrysowywa-
nia” obj´toÊci przez poszczególnych lekarzy, a tym samym poprawy jakoÊci leczenia. NiejasnoÊci zwiàzane z tym tematem po-
winny byç oceniane w ramach badaƒ klinicznych.
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Introduction
Conformal radiotherapy should follow ICRU 50 and
ICRU 62 criteria concerning target volume definition [1,
2]. In spite of the wide use of conformal techniques, target
volume definition remains a controversial issue in
radiotherapy for non-small-cell lung cancer (NSCLC).
There is no unanimous opinion among radiation oncolo-
gists regarding target’s delineation in NSCLC radio-
therapy. The delineation of the Gross Tumour Volume
(GTV) varies between physicians and depends on the
type of imaging used. The Clinical Target Volume (CTV)
definition is mainly methodology-dependent and is grossly
based on institutional opinions regarding the necessity
and extent of elective nodal irradiation (ENI). Micro-
scopic tumour extension around the GTV as a part of
the CTV isalso not precisely quantified and remains
a subject of study. Taking into account physiologic organs
motions and set-up inaccuracies, the Planning Target
Volume (PTV) is an especially important issue in NSCLC
radiotherapy. There are many methodological and
technological concepts dealing with the problem of
margin reduction for the PTV creation in view of
decreasing treatment toxicity.
The major source of uncertainty in determination
of the all three volumes is interclinician variability, which
could be related either to the lack of respect of protocols
or to the lack of a protocol in itself [3, 4]. There exists
data indicating that the implementation of departmental
protocols can reduce this source of errors. It is advocated
to create and consistently follow detailed departmental
protocols for target contouring [3].
The current state of art and controversies regarding
all three target volumes definitions in radiotherapy for
NSCLC are presented below.
Gross Tumour Volume (GTV) definition
The GTV according to ICRU Report 50 criteria is
defined as “the gross demonstrable extent and location of
the malignant growth” [1]. In case of radical radiotherapy
for NSCLC the GTV is related to the primary tumour
and mediastinal lymph nodes considered as metastatic.
The size of GTV, as determined in conformal
radiotherapy, appears as a highly prognostic factor for
survival and local tumour control [5]. It may be important
for the stratification of patients for future prospective
studies. Therefore special attention should be paid by
radiation oncologists in view of the unification of the
guidelines concerning GTV determination.
Evaluation of the extent of GTV is based mainly on
computed tomography (CT) images, supported by
bronchoscopic findings. The use of CT has radically
improved the possibility of evaluation of the mediastinal
extent of the disease. In the pre-CT era there were no
reliable means, besides surgery, to evaluate gross tumour
extension in the mediastinum. The inclusion of media-
stinal nodes in the irradiation field depended mostly on
clinical assumptions of the probability of nodal invasion.
In case of adenocarcinoma or squamous carcinoma no
systematic inclusion in the irradiation field of the media-
stinal area was recommended. For undifferentiated and
small-cell lung cancers the lymph node drainage areas
within the thorax were irradiated [6]. Although CT
remains the most common tool for the definition of the
“nodal GTV”, its sensitivity and specificity is evaluated to
be about 65% [7-9]. Taking into account the limits of CT
in evaluation of the “nodal GTV”, positron emission
tomography (PET) is implemented. The current practice
in radiation treatment planning is to consider lymph
nodes to be positive, if their dimension is 1 cm or greater
in the short axis and include them in the GTV [8, 10]. It
seems to be a reasonable clinical compromise, due to the
current low availability of the PET. The GTV within
mediastinum is contoured using the mediastinal window
setting. Evaluation of the “primary GTV” by CT seems
quite good, under the condition of keeping the slice
thickness to its minimum through the presumed area of
the GTV, except for cases with atelectasis. The contouring
of the “primary GTV” within pulmonary tissue should
be done using a lung window setting with the tissue
density corresponding to the level of –750 HU and
a window width of 850 HU recommended by Harris et al.
[3, 11]. In case of the use of commercial planning systems
with the density scales not corresponding to Hounsfield
units, a standardisation of the CT window setting for the
needs of treatment planning within each department is
recommended [3].
Tumours with atelectasis remain a special and
unresolved problem in GTV delineation. Sometimes it
is impossible to distinguish between both components
and such cases are considered as unsuitable for 3-D
conformal radiotherapy techniques. The radiologists’
opinion should be asked in such cases. In many cases
a reasonable clinical compromise can be achieved. Some
authors indicate that the use of special CT window setting
with a width of 150 HU and a level of 50 HU (”liver
window”) could allow to distinguish both components
[3]. Sometimes prior laser, or brachyterapy, can resolve
the atelectasis. We recommend, in cases of minor
component of atelectasis and/or possibility to encompass
it with respect of dose constraints for critical structures,
to consider the entire abnormality as the GTV. It
minimises the risk of missing the tumour and at present it
is a necessary and reasonable compromise. PET is also
considered as a useful tool for the distinction of tumours
from atelectasis, allowing, in many cases, to decrease the
size of portals in comparison with treatment planning
guided by CT only [12]. PET overestimates the tumour
volume in case of an inflammatory process. Therefore,
if the atelectasis is associated (as it is frequently seen)
with any degree of inflammation, PET can also give
inaccurate results. Lung cancer causing atelectasis
remains a continual challenge for radiation oncologists
and precise GTV delineation in such cases is actually not
possible today.
Magnetic resonance imaging is not in routine use
for GTV determination. It is only as accurate as CT in the
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evaluation of the mediastinum. It is more accurate in the
evaluation of the pulmonary hila, however this advantage
is not commonly exploited [13].
The use of PET in the GTV determination really
improves on accuracy, especially for mediastinal nodes.
Additionally, the use of PET for staging of patients
with NSCLC improves treatment results after radical
radiotherapy, which is related to the stage migration
resulting from a new method used [14]. Accuracy of PET
in the detection of metastases in the mediastinal lymph
nodes is about 90-95% [8, 14]. Despite a certain number
of problems with PET routine use in radiotherapy
planning, such as the high cost of method, overestimation
of GTV in case of associated inflammatory processes,
technical problems with matching images with 3-D CT
images, impossibility of detection of nodal micro-
metastases and low reliability for pulmonary hila, it is
a growing interest on implementation of this method for
the GTV definition [8, 10, 12].
Clinical target volume (CTV) definition
The CTV according to ICRU Report 50 criteria is defined
as “a tissue volume that contains a demonstrable GTV
and/or subclinical malignant disease that must be elimina-
ted” [1]. Besides the GTV it contains the subclinical
disease considered as microscopic malignant spread
around the GTV and regional lymphatic drainage area as
elective nodal irradiation volume.
The microscopic tumour extension as a margin
around the GTV is difficult to evaluate, because there is
no available imaging technique allowing us to measure it
directly. Giraud et al. [15] have evaluated microscopic
extension of the disease around macroscopic borders of
tumours in surgical resection specimens. They found that
usual margins around GTV of 5 mm can be inadequate
for CTV creation and postulate to increase them to 8
mm for adenocarcinoma and 6 mm for squamous cell
carcinoma in order to cover the microscopic extension
with a probability of 95%. Obviously, it is of crucial
importance to use the CT scanning with adequate
resolution and thin slices and appropriate window/level
setting, which probably allows to decrease margins for
CTV creation, but the exact dimension can not be, at
present, measured by radiological means. Therefore,
respecting measures for adequate CT resolution and
window setting, 5 mm margins for CTV delineation are
also a reasonable clinical compromise. Giraud et al. [15]
have also agreed with this solution for good quality CT
scanning. Spiculated tumour margins are associated with
greater microscopic extension [15], and usually they are
included in CTV, but sometimes it could be a result of an
inflammatory processes and there are no reliable imaging
methods for determining exact tumour borders in such
cases. The exact differentiation between GTV and CTV is
of capital importance if IMRT techniques are aimed to
deliver different dose per fraction levels for macroscopic
and microscopic disease extension.
The CTV in radiotherapy for NSCLC includes also
elective nodal irradiation (ENI) volume. It is related to
the area of lymphatic drainage, in which the metastases
were not detected by radiological means, but clinical and
surgical data indicate a high probability of microscopic
invasion. So, the ENI volume, as a part of the CTV,
remains an anatomic-clinical concept and now the
necessity of ENI is questionable. The opponents of ENI
may argue that NSCLC is known for its highly distant
metastatic potential and one could consider total body
as the CTV and an eradication of such an extent of the
disease by radiotherapy is not a conceivable idea. So,
mediastinal ENI volume could appear as a result of
a clinical compromise between the need of eradication of
Table I. N2 lymph node stations for lung cancer staging [28]
Lymph nodes group Location
Group 1: Highest mediastinal lymph nodes Above a horizontal line at the upper rime of the bracheocephalic vein
ascending to the left, where it crosses the trachea at its midline
Group 2: Upper paratracheal lymph nodes Above the upper margin of the aortic arch and below the inferior boundary
of group 1 location
Group 3: Prevascular and retrotracheal lymph nodes Pre- and retrotracheal
Group 4: Lower paratracheal lymph nodes Tracheo-bronchial angles, azygos vein and main bronchi within mediastinal
pleural envelope
Group 5: Subaortic (A-P window) lymph nodes At the aortic-pulmonary window
Group 6: Para-aortic lymph nodes Anterior and lateral to the ascending aorta, aortic arch or the innominate
artery
Group 7: Subcarinal lymph nodes Caudal and adjacent to the carina
Group 8: Paraoesophageal lymph nodes Adjacent to the wall of the oesophagus, excluding subcarinal nodes
Group 9: Pulmonary ligament lymph nodes Within the pulmonary ligament, including those of the lower part of
pulmonary veins
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subclinical disease and acceptable toxicity. The exact
extent of the ENI is debated and its impact on survival is
not proven. The concept of ENI was strongly supported
by the findings from RTOG studies, showing a strong
impact on survival and local control of proper inclusion of
the mediastinal area, including contralateral hilum in
radiation fields [16]. These findings led to the guidelines
concerning the irradiation volume, which have influenced
treatment policy for NSCLC up to date. It was stated
that: “...for upper and middle lobe lesions, the mediastinal
field should include 5 cm below the carina and supra-
clavicular areas. For lower lobe lesions, the lower margin
of the field is the diaphragm...” [17]. On the other hand, it
has been proven for NSCLC that the local control rate is
disappointingly low (below 20%), if conventional
radiation doses are employed [18]. For patients with the
early stages of the disease with poor pulmonary function
tests, omission of the ENI did not result in a significantly
increased regional (outside irradiation field) failure rate
and survival was not compromised by such a policy [19-
22]. A large number of the dose escalation studies using
conformal techniques were performed and the ENI
revealed to be the largest contributor to the pulmonary
and oesophageal toxicity [21-23]. Chemotherapy is largely
employed in the management of NSCLC. Recent
randomized studies have revealed that the concurrent
use of radiotherapy and chemotherapy improves survival
in comparison with sequential administration of both
modalities [24, 25]. However, this improvement in survival
is associated with significantly increased acute pulmonary
and oesophageal toxicity [26]. Thereafter, some authors
implement chemoradiation and/or dose escalation studies
using involved-fields irradiation, based on the concept
that chemotherapy may eradicate micrometastases and
ENI could reduce the therapeutic ratio by increasing
toxicity. The preliminary results of such an approach seem
promising with no increasing rate of out-field nodal
failure [10]. Omission of the ENI remains problematic,
because, as it was stated above, there are no absolutely
reliable diagnostic methods allowing to exclude the
presence of nodal occult metastases. Longer follow-up
and larger data are necessary to affirm the safety of this
treatment policy. On the other hand the use of PET for
treatment planning in NSCLC may improve evaluation of
the extent of the disease and minimise the risk of
omission of occult metastases [10]. In the absence of such
advanced technology, an ENI volume could be reduced to
the regions of the highest probability of nodal metastatic
invasion. Some authors systematically include the hilar
region to involved-fields radiotherapy for III stage
patients, because of the high probability of metastatic
invasion and the low reliability of CT, and even PET, for
the evaluation of this region [8, 9, 10, 13]. For 3 years we
have held to a protocol of the limited ENI for stage III
patients. It is based on surgical and radiological data
concerning the probability of nodal invasion [7, 27]. We
systematically include in the limited ENI volume,
considered here as the CTV, the ipsilateral hilum,
subcarinal nodes (group 7), ipsilateral lower paratracheal
(group 4) and pre- and retrotracheal nodes below upper
margin of the aortic arch (group 3). The aortic-pulmonary
window (group 5) and the right tracheo-bronchial angle
(group 4) nodes are included in the CTV regardless of the
site (right or left) of the tumour. Other nodal groups, if
uninvolved, such as the upper paratracheal (2) and
highest mediastinal (1) groups and paraoesophageal and
pulmonary ligament nodes for lower lobes are not
included in the CTV (for N2 lymph nodes stations
definition for lung cancer staging, see Table I) [28]. In
the 3-year follow-up period we have not observed any
outside radiation-port nodal failure in the absence of
local relapse and the volume of irradiated lung was
reduced, as compared to the traditional fields, as defined
by Rockman et al. [17].
A special problem for target volume’s definition is
adjuvant postoperative radiotherapy for NSCLC. The
GTV is not delineated, and the extent of the CTV is
certainly, regarding data on toxicity of postoperative
radiotherapy, to be reconsidered. In the PORT meta-
analysis it has been suggested that the excess mortality in
irradiated patients, especially in early stages, may be
reduced by careful patient selection, better treatment
quality and probably also by the reduction of irradiated
volumes [29]. Regarding the poor survival of patients
with contralateral nodal (N3) invasion, the inclusion of
contralateral nodes in the CTV is probably not justified
[7]. In our Institution the protocol of the limited ENI,
formulated as above, is ongoing for pN2 patients.
If there are no uniformly accepted guidelines
concerning the use and the extent of the ENI, the strict
formulation and respect of rules regarding CTV deter-
mination should be followed in each radiation oncology
department with a view on facilitating data comparison.
Planning Target Volume (PTV) definition
The PTV according to ICRU Report 50 criteria is defined
as “a geometrical concept used for treatment planning,
and it is defined to select appropriate beam sizes and
beam arrangements, to ensure that the prescribed dose is
actually delivered to the CTV” [1]. A new ICRU Report
62 (supplement to ICRU 50) [2] detailed the data
necessary to define margins between CTV and PTV
introducing a concept of the Internal Margins (IM)
related to the physiologic movements of the CTV and
the Set-up Margins (SM) taking into account all un-
certainties in patient-beam positioning. IM and SM are to
be added to the CTV for the PTV determination [2].
Determination of IM is the real challenge in
conformal radiotherapy for NSCLC. The heart and the
great vessels beat, but this especially concerns respiratory
movements – the factual major source of uncertainty.
Respiratory movements differ in relation to the CTV
location and change with direction of motion. Movements
in the craniocaudal direction are larger than in the
transversal plan and can exceed 1 cm. Ekberg et al. [30]
postulate the increase of margins in the craniocaudal
direction to 15 mm, or taking individual measures for
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each patient. Many advanced technologies are investi-
gated in order to eliminate the respiratory movements
during the treatment planning and delivery. They consist
grossly of treatment delivery in one precise phase of
respiration [31]. Active breathing control and similar
methods seem to be the melody of the nearest future,
because many companies develop treatment planning
and delivery systems allowing to treat patients in full
control of respiratory movements. Respiratory mobility is
of special importance for involved-fields techniques,
because of increased risk of missing the CTV. Therefore,
margins for nodal mediastinal mobility were evaluated.
Margins of 5 mm seem sufficient at this level, probably
except for subcarinal nodes, as this region needs further
evaluation due to presumed greater mobility of the carina
[32].
Set-up margins are related to mechanic uncertainties
of the equipment, variations in patient positioning,
transfer set-up errors in the CT – simulator – accelerator
axis, human error and dosimetric uncertainties [2]. These
latter are of a special interest for lung cancer treatment
planning. Radiation oncologists could be pleased with
treatment plans prepared for lung cancer with high energy
photons. However, a penumbra areas are probably
underestimated by commercial planning systems, because
of the limited accuracy of penumbras calculated by
existing dose calculation models in low density materials
(e.g. lung) at high energies (15 MV et up) [33, 34]. The
choice of energy for lung cancer conformal radiotherapy
should take these facts into account.
Data concerning all these listed factors should be
collected in each radiotherapy department for internal
and set-up inaccuracy and the final decision on dimension
of margins for PTV determination should be based on
this knowledge.
Conclusions
In a number of areas we are still facing more queries
than answers in order to define target volumes for
radiotherapy of NSCLC. Most problems related to the
target volumes definition in radiotherapy for NSCLC
follow no precise, commonly accepted rules. In case of
unproven clinical strategies special attention should be
focused on creating detailed departmental protocols in
order to avoid any errors and to find the best treatment
policy for the future. Each department should be
consistent in its approach to target contouring and
definition. Data collected from these clinical experiences
could form the basis for future guidelines or randomized
studies.
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